Ten years ago Innovative Medicines Initiative Joint Undertaking (IMI-JU) was created as a unique public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) aiming to accelerate development of innovative medicines.
‍

On April 2008 IMI-JU launched its first call for proposals. Carlos Díaz and Eva Molero were at that time working at the Barcelona Municipal Institute for Medical Research managing European projects. That same year SYNAPSE was created, initially to manage a public private partner in AIDS vaccine – HIVACAT.
‍

‍
The first IMI project in which SYNAPSE was a partner was the eTOX project, steming from Call 1. The eTOX objective to Integrate bioinformatics and chemoinformatics approaches by developing expert systems allowing the in-silico prediction of toxicities. The eTOX project was started in January 2010. From 2008 SYNAPSE and IMI-JU have grown side by side. The IMI-JU has launched over 100 projects over the last decade, and 13 of them are managed by SYNAPSE. We are proud that during this 10 years we have developed a strong position in the Innovative Medicine Initiative programme.

‍

Today, SYNAPSE is most present Spanish partner and one of the top 5 SMEs in Europe involved in IMI-JU projects. We have collaborated with more than 100 universities and research organisations,  and nearly 100 pharmaceutical and private companies that, together with other entities, sums up to more than 300 partners we are working with.

Overall, SYNAPSE has managed over 25 projects over the last ten years. The company has been growing sustainably in all fronts, and today SYNAPSE is composed by a team of 19 highly skilled people managing 13 IMI projects with total budget over 300M€.

‍
‍

You can check out SYNAPSE`s involvement in the IMI projects using the IMI interactive map.

Or visiting the Portfolio section.

‍

‍